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Abstract 
Hepatitis C is a major cause of liver related morbidity and mortality worldwide and represents a major public health prob-
lem. Depending on genomic organization, the virus is divided into six genotypes and a number of subtypes. Different 
genotypes are seen in different parts of the world. Genotype one is difficult to treat, while genotypes 2 and 3 are easy to 
treat. Therefore, identification of HCV genotype in patients is necessary to begin and follow up the treatment. In this study, 
viral genomic materials of 214 patients’ sera were detected by nested-RT PCR. Based on genomic differences among dif-
ferent genotypes, the PCR products were digested with proper enzymes and studied by RFLP. Except for one, sequencing of 
14 samples, representative of all genotypes, confirmed the results of PCR-RFLP. The results of PCR-RFLP were as follows: 
1a (52.88%), 1b (14.01%), 3a (27.57%), 2a (2.1%), 4 (3.44%). This indicates that a high percentage of HCV infected pa-
tients in Iran are infected with 1a or 3a genotypes. These findings reveal that the pattern of HCV genotypes in Iran differs 
from those of other middle-eastern countries.  
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Introduction 
Hepatitis C virus (HCV) is an important cause 
of chronic liver disease. HCV causes 20% of 
acute hepatitis cases, 70% of all chronic hepati-
tis cases, 40% of all cases of cirrhosis of the 
liver, 60% of hepatocellular carcinomas, and 
30% of liver transplants in Europe (1). Recently, 
HCV infection has drawn great attention due to 
similar risk factors and co-infectivity with HIV 
infection. WHO estimation of HCV prevalence, 
suggests that up to 3% of the worlds population 
(170 million) have been infected with HCV (2). 
In Iran, it seems that the prevalence of general 
population is less than 1 percent, which is much 
lower than that of most of neighboring coun-
tries in this region (2). However, the infection is 
emerging mostly due to problems of intrave-
nous drug abuse and needle sharing in the coun-
try (2). On the other hand, increase in number 
of centers providing hemodialysis and transfu-
sion facilities for hemoglobinopathies generated 
new sources and susceptible populations in Iran 
(3). HCV, the causative agent of most cases of 
non A, non B hepatitis, exists as a heterogene-
ous group of viruses sharing at least 65% homol-
ogy among different strains. This virus has a 
positive sense, single stranded RNA genome of 
approximately 9.5 kb. Consistent with related 
members of the Flaviviridae family, HCV demon-
strates a high degree of sequence variation through-
out its genome. Sequence analysis of multiple 
strains of HCV has demonstrated that the nucleo-
tide sequence can differ by as much as 30% (4). 
However, the levels of heterogeneity differ 
considerably among various regions of the vi-
rus. For example, sequence variation ranges 
from as little as 10% in the 5' untranslated re-
gion (5'-UTR) to as much as 50% or more 
within the E1 region (5, 6). There are three func-
tional regions of the genome, the 5'-UTR, the 
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coding region encoding the structural and non-
structural viral proteins, and the 3'-UTR (7). 
The polyprotein is processed into structural and 
nonstructural proteins. The core and the two 
envelope proteins (E1 and E2) are parts of the 
virion (7-9). HCV isolates from around the 
world can be divided into distinct major groups 
or genotypes with about 66 to 69% nucleotide 
similarity, which can in turn be divided further 
into subtypes with about 77 to 80% nucleotide 
similarity (10). Phylogenetic analysis may aid 
in the separation of sequences into distinct types 
(11). Six major genotypes (HCV-1 to HCV-6) 
have been described so far, each containing 
multiple subtypes (e.g., 1a, 1b, etc). The isolates 
formerly published as genotypes 7 to 11 are now 
considered subtypes within genotypes 3 (sub-
type 10) and 6 (subtypes 7, 8, 9, and 11) (12). 
The HCV genotypes have been determined 
primarily based on analysis of partial genome 
sequences. The most extensive database exists 
for the 5'-UTR, core, E1, and NS5B (13- 17). 
Whereas the 5'-UTR is highly conserved and 
therefore preferred for diagnosis, the core, en-
velope, and NS5B regions are less conserved 
and therefore highly discriminative and may be 
preferred for subtyping (17). 
The standard and most definitive method for 
HCV genotyping is sequencing of a specific 
PCR-amplified portion of the HCV genome 
obtained from the patient, followed by phy-
logenetic analysis. Investigators of HCV geno-
typing have used sequence analysis of HCV NS5, 
core, E1, and 5'-UTRs. However; direct sequenc-
ing of amplified DNA does not usually identify 
mixed infections with two different HCV geno-
types (17). Other methods that have been re-
ported depend mainly on the amplification of 
HCV RNA from clinical specimens, followed 
by either reamplification with type-specific prim-
ers or hybridization with type-specific probes 
(18-21) or by digestion of PCR products with 
restriction endonucleases that recognize geno-
type-specific cleavage site (22). HCV genotyp-
ing by using type-specific primers was first in-
troduced by Okamoto et al. using primers spe-
cific for the core region (23). This method 
lacked acceptable sensitivity and specificity 
(24). Several DNA hybridization assays for 
HCV genotyping have been described. A commer-
cial kit for HCV genotyping has been intro-
duced in Europe by Innogenetics (InnoLipa, 
Belgium) and is based on hybridization of 5'-
UTR amplification products with genotype-
specific probes (25). Others have used restric-
tion enzymes to determine viral genotype by 
Restriction Fragment Length Polymorphism 
(RFLP). In this method, a PCR-amplified DNA 
fragment is digested into fragments with differ-
ent lengths by enzymes (restriction endonucle-
ases) that recognize cleavage sites specific for 
each genotype (26). Although all these methods 
are able to identify the major genotypic groups, 
only direct nucleotide sequencing is efficient in 
discriminating subtypes (27, 28). 
In the current study, we have typed HCV strains 
with RFLP rapidly and reliably by digesting the 
amplified DNA from the primary specimens by 
selected restriction enzymes and some by sequencing.  
 
Materials and Methods 
Samples     During 2003-2004, 214 sera from 
HCV-infected Iranian patients with chronic 
hepatitis, referred to Keivan Virology Labora-
tory (Tehran, Iran) were studied. Etiological 
factors other than chronic HCV infection were 
ruled out in all cases. All patients had elevated 
serum aminotransferases for at least 6 months, a 
positive test for anti-HCV antibodies (third-
generation ELISA [Ortho Diagnostics, Raritan, 
N. J.]), and HCV RNA in serum by reverse 
transcription nested PCR for the 5'-UTR of the 
HCV genome (29, 30). The mean age of pa-
tients was 41 (range, 13 to 70) yr. One hundred 
forty one patients were male and 73 were fe-
male. One hundred seventy nine patients had 
one, two, or even three of the following criteria: 
102 had a history of blood transfusion, 54 had a 
history of intravenous drug use (IVDU), 65 had 
long duration of hemodialysis and thalassemia, 
43 had been tattooed, 138 had a history of ma-
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jor surgery, and 76 had minor surgery. The pos-
sible source of infection was not determined in 
35 patients. Results of histological investiga-
tions revealed mild chronic hepatitis in 59 cases, 
moderate chronic hepatitis in 49, and severe 
chronic hepatitis in 35 patients. There was no 
histological information for 71 patients. Prether-
apy blood samples were obtained under appropri-
ate conditions to improve preservation of RNA 
and immediately stored at -70 °C until tested (31).  
HCV RNA extraction and cDNA synthesis 
For detection of HCV RNA in serum and for 
genotyping studies, RNA was extracted from 
fifty µl of serum by acid guanidinium-isothio-
cyanate-phenol- chloroform method (32), then 
precipitated with isopropanol, and rinsed with 
70% cold ethanol. The RNA pellet was resus-
pended in 25 µl of diethyl pyrocarbonate (DEPC) 
treated water. cDNA was synthesized from 7 µl 
of RNA with 200 U of AMV reverse transcriptase 
(Promega, USA) AMV reverse transcriptase 5X 
reaction buffer, 10 mM of the dNTPs in the pres-
ence of 40 U random primers and 20 U of RNase 
inhibitor (Promega, USA). The guidelines of 
Kwok and Higuchi (33) were strictly observed to 
prevent carryover contamination, and appropri-
ate negative controls for RNA extraction, cDNA 
synthesis, and PCRs were routinely included in 
each PCR round. The amplification procedure 
involved reverse transcription at 42°C for 30 min 
and RNase inhibitor inactivation at 94°C for 3 min. 
Primers     For RT-PCR and nested PCR, four 
oligonucleotide primers for the 5'-UTR of HCV 
were designed using generunr (Hastings soft-
ware) and synthesized at the SeqLab Company 
(Germany). In the first round of PCR, the prim-
ers corresponded to HCV-1 sense oriented nu-
cleotides -268 to -251 F (AGCGTCTAGCCATG-
GCGT), numbered according to Bukh et al. (10), 
and antisense nucleotides -4 to -22 R (GCACG-
GTCTACGAGACCT). For the second round, the 
primer FN (GTGGTCTGCGGAACCGG) corre-
sponded to sense-oriented nucleotides -199 to    
-183 and RN (GGGCACTCGCAAGCACCC) 
corresponded to antisense nucleotides-26 to -43. 
PCR     In the first round of PCR, reagent I 
composed of fifty mM  KCl, 1.5 Mm MgCl 2, 
10 mM  Tris-HCl (pH 9.0), 1X Taq DNA po-
lymerase buffer (Fermentas, Ukraine), 200 µM 
each of the four dNTPs, 0.4 µM each of the first 
round primers and 1 U Taq DNA polymerase 
(Fermentas, Ukraine), were used. The amplifi-
cation procedure included denaturation at 94°C 
for 3 min, followed by 35 cycles of amplifica-
tion for 45 s each at 94 °C, 58 °C, and 72 °C 
and finally 5 min at 72 °C for final extension.  
For the second round, PCR reagent II, com-
posed of 50 mM KCl, 1.5 mM MgCl 2, 10 mM 
Tris-HCl (pH 9.0), 1X Taq DNA polymerase 
buffer (Fermentas) 200 µM each of the four 
dNTPs, 0.4 µM each of the second round prim-
ers and 1 U Taq DNA polymerase, were used. 
The amplification procedure was as follows: 
predenaturation at 94 °C for 3 min, 25 cycles for 
1 min steps at 94 °C, 65 °C, and 72 °C, respec-
tively, and final extension at 72°C for 4 min. 
Fifteen µl out of the 25 µl of PCR and nested-
PCR products were analyzed by horizontal gel 
electrophoresis on 2% agarose in TBE 1X buffer 
at 100 V/50 min. A single, 264 bp band was some-
times visible after the first round, but a 174 bp 
was preserve in all cases after the second PCR. 
Genotyping by RFLP     Total volume of each 
nested-PCR product (25 µl) was divided into 
three tubes containing appropriate buffers. Re-
striction enzymes, Apa I, Hinf I, EcoR II and 
Bsh1236 (Fermentas, Ukraine) used as the fol-
lowing combinations: 1.Apa I / Hinf I; 2. EcoR 
II / Hinf I; 3. Bsh1236 I. Bsh1236 I was found 
to be informative by sequence analysis of dif-
ferent strains, while other enzymes had been 
reported previously by McOmish et al. (34). 
Tubes were incubated with 1 µl of the enzyme 
mixture for 3 h at 37 °C. The digests were heated 
for 5 min before analysis by vertical 12% poly-
acryl amide gel electrophoresis. After ethidium 
bromide staining, the DNA fragments were identi-
fied under ultraviolet light. Molecular weight 
100 bp plus marker (Fermentas, Ukraine) and 
undigested PCR products was included in each 
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analysis. The genotypes were deduced from the 
fragmentation patterns of the amplified DNA. 
Direct sequencing of 5'-UTR    PCR fragments 
were cut out from the agarose gel and purified 
using a mini column system (MN Germany). 
Cycle sequencing was performed using the ABI 
PRISM The BigDye Terminator v3.1 Cycle Se-
quencing Kit (USA) following the manufac-
turer's instructions. Inner PCR primers (FN, RN) 
were used as sequencing primers to obtain the 
entire nucleotide sequences of the two strands. 
Sequencing reactions were prepared according to 
the manufacturer's instructions before automatic 
electrophoresis of the sequencing products by 
an ABI PRISM 3700 (USA) Genetic Analyzer. 
 
Results 
Table one demonstrates cutting sites of Hinf I, 
Apa I, EcoR II and Bsh1236 I restriction en-
zymes for different strains of HCV as published 
by Bukh et al. (EMBL/Gen Bank/DDBJ, acces-
sion No.11443). This table shows fragments 
yielded upon restriction enzyme digestion of 5'-
UTR region. The cutting sites of restriction en-
zymes are shown (A) Apa I/Hinf I; (B) EcoR II 
/Hinf I; (C) Bsh1236 I.  
Fig. 1 demonstrates the analytical polyacryla-
mide gel electrophoresis of HCV types 1a, 1b, 
2a, 3a and 4 after digestion of the amplified 
DNA with the selected restriction enzymes. 
Genotyping of 214 sera from patients who were 
either recently infected by HCV or with history 
of previous HCV infection and positive PCR 
results was performed. Study of results of se-
quencing of 14 PCR positive sera demonstrated 
that except in 1 case, results of RFLP genotyp-
ing and sequencing were comparable. The RFLP 
result indicated 1b subtype but the sequencing 
showed 3 h. Table 2 shows the results of sequenc-
ing in comparison to those of RFLP. The results 
of PCR-RFLP were as follows: 1a (52.88%), 1b 
(14.01%), 3a (27.57%), 2a (2.1%), 4 (3.44%). 
This indicates that a high percentage of HCV 
infected patients in Iran are infected with 1a or 
3a genotypes (Table 3). 
Analysis of population previously infected with 
HCV showed that only 26 % were above 50 yr 
of age (Table 4). The most frequent genotype in 
patients above 50 was 3a, while 1a genotype 
was more prevalent in patients under 50 yr old. 
Hemodialysis patients and cases by known his-
tory of transfusion were known to be infected by 
only subtypes 1a and 3a. Also the patients under 
30 yr old were infected by only subtypes 1a and 
3a. A higher percentage of mixed infection (1a/ 
3a) was observed in IVDU and Thalassemic pa-
tients in comparison with other groups.     
The 12 HCV sequences (5'-UTR) from the Ira-
nian patients have been submitted to GenBank; 
the 5'-UTR sequences were given these accession 
numbers: AY523463 to AY523466, AY515300, 
and AY545671 to AY545678. 
                                       A                  B                 C                   D     E 
     
 
Fig. 1: 12% polyacrylamide gel electrophoresis of the digestion products of the amplified DNA from different genotypes. 
Marker; 50bp (Fermentas, Ukraine) A; 1a (97bp, 97bp, 129bp), B; 1b (97bp, 97bp, 99bp), C; 2a (97bp, 174bp, 174bp), 
D; 3a (129bp, 145bp, 99bp), E; 4(97bp, 145bp, 129bp)             
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Table 1: RFLP of the 174 bp DNA fragment from 5'-
UTR of different HCV genotypes. (1) Apa I/Hinf I; (2) 
EcoR II/ Hinf I; (3) Bsh1236 I. The sequences were from 




Tube A Tube B Tube C 
1a 97bp 97bp 129bp 
1b 97bp 97bp 99bp 
2a 97bp 174bp 174bp 
2b 174bp 174bp 174bp 
3a 129bp 145bp 99bp 
3b 97bp 145bp 99bp 
4 97bp 145bp 129bp 
5 97bp 174bp 99bp 
6 97bp 97bp 174bp 
 
Table 2: Comparison of RFLP typing and Sequencing 
 
Sequencing  
RFLP 1a 1b 2a 3a 4 3h 
1a 3 - - - - - 
1b - 3 - - - - 
2a - - 1 - - - 
3a - - - 4 - - 
4 - - - - 2 - 
1b - - - - - 1 
 
Table 3: Hepatitis C Virus genotypes in 214 Iranian 
patients with RFLP method 
 
Genotype No. (%) 
1a 117 (52.88) 
1b 28 (14.01) 
2a 1 (2.1) 
3a 63 (27.57) 
4 5 (3.44) 
Total 214 (100) 
Table 4: HCV genotype distribution among Iranian subjects as determined by 5'-UTR RFLP analysis 
 
Level (n) HCV Genotype: No. (%)  
 1a 1b 2a 3a 4 1a/3a 
Age(year)       <30                    60 67 - - 33 - - 
                      30-50 98 50 16 1 25 3 5 
                      >50 56 33 11 - 45 - 11 
Gender          Male                   141 49 11 1 32 3 4 
                     Female 73 63 11 - 21 1 4 
Transfusion 102 61 - - 39 - - 
Hemodialysis 32 51.4 - - 48.6 - - 
IVDU 54 59.7 8 1 20.3 3 8 
Thalassemic 33 61 11 - 21 1 6 
Tattoo 43 61 13 - 26 - - 
Minor surgery 76 51 17 - 24 - 8 
Major surgery 138 55 13 - 32 - - 
 
Discussion 
Hepatitis C Virus (HCV) is one of the main causes 
of acute and chronic hepatitis. The virus is distrib-
uted worldwide with prevalence varying between 
different countries from 0.2 up to 40% (35). 
HCV is highly variable, leading to the classifica-
tion of at least six genotypes, each with several 
subtypes. This heterogeneity is, at least partly, 
responsible for lack of availability of an effec-
tive vaccine (36). 
Investigators of HCV genotyping have used 
sequence analysis of HCV NS5, Core, E1 and 
5'-UTRs. However, direct sequencing is not practi-
cal on a large scale. RFLP has been used widely 
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for this purpose, especially for screening of large 
number of specimens (37). 
The use of 5'-UTR assay designed for the de-
tection of HCV in clinical specimens provides a 
sensitive, standardized amplification protocol 
specifically designed for large-volume testing 
and rapid turnaround time and is also used 
widely for HCV genotyping by different inves-
tigators. In this report, we have focused on 
chronically infected group of patients, to de-
termine the most prevalent genotypes in Iran. 
RFLP of HCV PCR positive sera and sequenc-
ing of 174 bp fragment of 5'-UTR region was 
used to achieve this purpose. By RFLP, we 
have classified all of HCV isolates from Iranian 
patients to 5 genotypes. We could not determine 
genotype of one sample by RFLP, and through 
sequencing it was determined to be subtype 3b. 
We have recently shown that subtypes 1b and 
3b could be very similar in their 5'-UTR region 
(38). It seems that sequencing of another region 
of HCV genome (Core, E1, and NS5B) followed 
by phylogenetic analysis may clarify the differ-
ences between these two subtypes.    
In the first report in Iranian patients, the preva-
lence of specific genotypes in 15 samples was 
studied in Tehran and the results were as fol-
lows: Type I/1a in seven cases, Type II/1b in 
three cases-and Type V/3a in four patients (39). 
One sample disclosed Type 4. A recently pub-
lished article in Iranian patients with anti-HCV 
Ab positive from Tehran and five cities from 
different locations of Iran, showed that genotype 
1a was predominant (47%), and 3a, 1b, as well 
as 4 were 36%, 8%, and 7%, respectively (40). 
There are limitation in determining the precise 
geographic distribution of HCV genotypes and 
subtypes in many areas of the world. Only a 
few countries have detailed information about 
the molecular epidemiology of HCV. In West-
ern Europe, the most common type is 1a, whereas 
in southern and Eastern Europe type 1b is more 
common (26, 41).   
There is also difference between southeastern 
Europe and Turkey (mainly type 1b) and the Mid-
dle East. The major genotype in the Republic of 
Yemen, Kuwait, Iraq, and Saudi Arabia is type 
4 (42). 
It was concluded that the HCV genotypes pat-
tern in Iran differs from other middle-eastern coun-
tries and is more similar to Western European region.  
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